Pharvaris N.V. (PHVS) Stock Competitors & Peer Comparison
See (PHVS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHVS | $31.59 | +1.61% | 2.2B | -10.00 | -$3.16 | N/A |
| NVO | $41.02 | -4.50% | 182.2B | 9.63 | $4.26 | +4.37% |
| VRTX | $442.96 | -0.87% | 112.4B | 26.29 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $611.34 | -3.79% | 63B | 14.91 | $40.99 | +0.59% |
| ARGX | $882.41 | -1.00% | 54.6B | 39.13 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.16 | -3.59% | 39B | 73.59 | $3.97 | N/A |
| RVMD | $148.49 | -0.50% | 31.6B | -20.86 | -$7.12 | N/A |
| RPRX | $54.86 | -1.81% | 23.6B | 28.87 | $1.90 | +1.66% |
Stock Comparison
PHVS vs NVO Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, NVO has a market cap of 182.2B. Regarding current trading prices, PHVS is priced at $31.59, while NVO trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas NVO's P/E ratio is 9.63. In terms of profitability, PHVS's ROE is -0.67%, compared to NVO's ROE of +0.66%. Regarding short-term risk, PHVS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check NVO's competition here
PHVS vs VRTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, VRTX has a market cap of 112.4B. Regarding current trading prices, PHVS is priced at $31.59, while VRTX trades at $442.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas VRTX's P/E ratio is 26.29. In terms of profitability, PHVS's ROE is -0.67%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, PHVS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check VRTX's competition here
PHVS vs VRNA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PHVS is priced at $31.59, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PHVS's ROE is -0.67%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, PHVS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check VRNA's competition here
PHVS vs REGN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, REGN has a market cap of 63B. Regarding current trading prices, PHVS is priced at $31.59, while REGN trades at $611.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas REGN's P/E ratio is 14.91. In terms of profitability, PHVS's ROE is -0.67%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PHVS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check REGN's competition here
PHVS vs ARGX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ARGX has a market cap of 54.6B. Regarding current trading prices, PHVS is priced at $31.59, while ARGX trades at $882.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ARGX's P/E ratio is 39.13. In terms of profitability, PHVS's ROE is -0.67%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, PHVS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ARGX's competition here
PHVS vs SGEN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PHVS is priced at $31.59, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PHVS's ROE is -0.67%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PHVS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check SGEN's competition here
PHVS vs ALNY Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ALNY has a market cap of 39B. Regarding current trading prices, PHVS is priced at $31.59, while ALNY trades at $292.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ALNY's P/E ratio is 73.59. In terms of profitability, PHVS's ROE is -0.67%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, PHVS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ALNY's competition here
PHVS vs RVMD Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RVMD has a market cap of 31.6B. Regarding current trading prices, PHVS is priced at $31.59, while RVMD trades at $148.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RVMD's P/E ratio is -20.86. In terms of profitability, PHVS's ROE is -0.67%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, PHVS is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RVMD's competition here
PHVS vs RPRX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, PHVS is priced at $31.59, while RPRX trades at $54.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RPRX's P/E ratio is 28.87. In terms of profitability, PHVS's ROE is -0.67%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, PHVS is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check RPRX's competition here
PHVS vs UTHR Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, PHVS is priced at $31.59, while UTHR trades at $544.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas UTHR's P/E ratio is 20.14. In terms of profitability, PHVS's ROE is -0.67%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PHVS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check UTHR's competition here
PHVS vs BNTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, PHVS is priced at $31.59, while BNTX trades at $85.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BNTX's P/E ratio is -14.54. In terms of profitability, PHVS's ROE is -0.67%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, PHVS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BNTX's competition here
PHVS vs ROIV Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ROIV has a market cap of 20.5B. Regarding current trading prices, PHVS is priced at $31.59, while ROIV trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ROIV's P/E ratio is -52.76. In terms of profitability, PHVS's ROE is -0.67%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, PHVS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ROIV's competition here
PHVS vs INSM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, INSM has a market cap of 20.4B. Regarding current trading prices, PHVS is priced at $31.59, while INSM trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas INSM's P/E ratio is -16.35. In terms of profitability, PHVS's ROE is -0.67%, compared to INSM's ROE of -1.30%. Regarding short-term risk, PHVS is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check INSM's competition here
PHVS vs BGNE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PHVS is priced at $31.59, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PHVS's ROE is -0.67%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, PHVS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BGNE's competition here
PHVS vs INCY Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, INCY has a market cap of 20.1B. Regarding current trading prices, PHVS is priced at $31.59, while INCY trades at $100.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas INCY's P/E ratio is 14.21. In terms of profitability, PHVS's ROE is -0.67%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PHVS is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check INCY's competition here
PHVS vs MRNA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, PHVS is priced at $31.59, while MRNA trades at $47.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MRNA's P/E ratio is -5.85. In terms of profitability, PHVS's ROE is -0.67%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, PHVS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MRNA's competition here
PHVS vs DNA-WT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PHVS is priced at $31.59, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PHVS's ROE is -0.67%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, PHVS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check DNA-WT's competition here
PHVS vs NBIX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, NBIX has a market cap of 16.4B. Regarding current trading prices, PHVS is priced at $31.59, while NBIX trades at $163.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas NBIX's P/E ratio is 25.06. In terms of profitability, PHVS's ROE is -0.67%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, PHVS is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check NBIX's competition here
PHVS vs GMAB Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, GMAB has a market cap of 15.2B. Regarding current trading prices, PHVS is priced at $31.59, while GMAB trades at $24.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas GMAB's P/E ratio is 18.79. In terms of profitability, PHVS's ROE is -0.67%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, PHVS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check GMAB's competition here
PHVS vs JAZZ Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, PHVS is priced at $31.59, while JAZZ trades at $232.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas JAZZ's P/E ratio is 1933.67. In terms of profitability, PHVS's ROE is -0.67%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, PHVS is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check JAZZ's competition here
PHVS vs BBIO Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, PHVS is priced at $31.59, while BBIO trades at $67.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BBIO's P/E ratio is -18.01. In terms of profitability, PHVS's ROE is -0.67%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, PHVS is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BBIO's competition here
PHVS vs EXEL Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, EXEL has a market cap of 13B. Regarding current trading prices, PHVS is priced at $31.59, while EXEL trades at $51.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas EXEL's P/E ratio is 17.13. In terms of profitability, PHVS's ROE is -0.67%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, PHVS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check EXEL's competition here
PHVS vs ASND Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ASND has a market cap of 12.7B. Regarding current trading prices, PHVS is priced at $31.59, while ASND trades at $205.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ASND's P/E ratio is 23.39. In terms of profitability, PHVS's ROE is -0.67%, compared to ASND's ROE of -56.42%. Regarding short-term risk, PHVS is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ASND's competition here
PHVS vs KRTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PHVS is priced at $31.59, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PHVS's ROE is -0.67%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PHVS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KRTX's competition here
PHVS vs IONS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, PHVS is priced at $31.59, while IONS trades at $73.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas IONS's P/E ratio is -36.59. In terms of profitability, PHVS's ROE is -0.67%, compared to IONS's ROE of -0.59%. Regarding short-term risk, PHVS is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check IONS's competition here
PHVS vs AXSM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, PHVS is priced at $31.59, while AXSM trades at $235.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas AXSM's P/E ratio is -63.21. In terms of profitability, PHVS's ROE is -0.67%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, PHVS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check AXSM's competition here
PHVS vs RNAM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PHVS is priced at $31.59, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PHVS's ROE is -0.67%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PHVS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RNAM's competition here
PHVS vs SMMT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, PHVS is priced at $31.59, while SMMT trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas SMMT's P/E ratio is -8.87. In terms of profitability, PHVS's ROE is -0.67%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, PHVS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check SMMT's competition here
PHVS vs BMRN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, PHVS is priced at $31.59, while BMRN trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BMRN's P/E ratio is 40.68. In terms of profitability, PHVS's ROE is -0.67%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, PHVS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BMRN's competition here
PHVS vs MDGL Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, PHVS is priced at $31.59, while MDGL trades at $467.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MDGL's P/E ratio is -34.61. In terms of profitability, PHVS's ROE is -0.67%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, PHVS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MDGL's competition here
PHVS vs ARWR Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, PHVS is priced at $31.59, while ARWR trades at $73.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ARWR's P/E ratio is -32.54. In terms of profitability, PHVS's ROE is -0.67%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, PHVS is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ARWR's competition here
PHVS vs RXDX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PHVS is priced at $31.59, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PHVS's ROE is -0.67%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PHVS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RXDX's competition here
PHVS vs KRYS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, PHVS is priced at $31.59, while KRYS trades at $301.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas KRYS's P/E ratio is 40.45. In terms of profitability, PHVS's ROE is -0.67%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PHVS is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KRYS's competition here
PHVS vs IMGN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PHVS is priced at $31.59, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PHVS's ROE is -0.67%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PHVS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check IMGN's competition here
PHVS vs CYTK Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, PHVS is priced at $31.59, while CYTK trades at $67.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CYTK's P/E ratio is -9.91. In terms of profitability, PHVS's ROE is -0.67%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, PHVS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CYTK's competition here
PHVS vs HALO Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, PHVS is priced at $31.59, while HALO trades at $70.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas HALO's P/E ratio is 24.82. In terms of profitability, PHVS's ROE is -0.67%, compared to HALO's ROE of +1.26%. Regarding short-term risk, PHVS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check HALO's competition here
PHVS vs BPMC Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PHVS is priced at $31.59, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PHVS's ROE is -0.67%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, PHVS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check BPMC's competition here
PHVS vs TECH Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, PHVS is priced at $31.59, while TECH trades at $52.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TECH's P/E ratio is 75.21. In terms of profitability, PHVS's ROE is -0.67%, compared to TECH's ROE of +0.05%. Regarding short-term risk, PHVS is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TECH's competition here
PHVS vs CERE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PHVS is priced at $31.59, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CERE's P/E ratio is -16.47. In terms of profitability, PHVS's ROE is -0.67%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PHVS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CERE's competition here
PHVS vs CORT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CORT has a market cap of 7.9B. Regarding current trading prices, PHVS is priced at $31.59, while CORT trades at $73.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CORT's P/E ratio is 209.51. In terms of profitability, PHVS's ROE is -0.67%, compared to CORT's ROE of +0.08%. Regarding short-term risk, PHVS is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CORT's competition here
PHVS vs IBRX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, PHVS is priced at $31.59, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas IBRX's P/E ratio is -8.44. In terms of profitability, PHVS's ROE is -0.67%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, PHVS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check IBRX's competition here
PHVS vs MTSR Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PHVS is priced at $31.59, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PHVS's ROE is -0.67%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, PHVS is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MTSR's competition here
PHVS vs ALKS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ALKS has a market cap of 7.1B. Regarding current trading prices, PHVS is priced at $31.59, while ALKS trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ALKS's P/E ratio is 47.17. In terms of profitability, PHVS's ROE is -0.67%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, PHVS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ALKS's competition here
PHVS vs MRUS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PHVS is priced at $31.59, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PHVS's ROE is -0.67%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, PHVS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MRUS's competition here
PHVS vs ACLX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $31.59, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PHVS's ROE is -0.67%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PHVS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ACLX's competition here
PHVS vs PCVX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, PCVX has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $31.59, while PCVX trades at $46.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas PCVX's P/E ratio is -6.72. In terms of profitability, PHVS's ROE is -0.67%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, PHVS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PCVX's competition here
PHVS vs ABVX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, PHVS is priced at $31.59, while ABVX trades at $101.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ABVX's P/E ratio is -18.94. In terms of profitability, PHVS's ROE is -0.67%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PHVS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ABVX's competition here
PHVS vs RETA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PHVS is priced at $31.59, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RETA's P/E ratio is -66.29. In terms of profitability, PHVS's ROE is -0.67%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PHVS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RETA's competition here
PHVS vs NUVL Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, NUVL has a market cap of 6.5B. Regarding current trading prices, PHVS is priced at $31.59, while NUVL trades at $88.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas NUVL's P/E ratio is -14.60. In terms of profitability, PHVS's ROE is -0.67%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PHVS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check NUVL's competition here
PHVS vs IMVT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, PHVS is priced at $31.59, while IMVT trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas IMVT's P/E ratio is -11.12. In terms of profitability, PHVS's ROE is -0.67%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, PHVS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check IMVT's competition here
PHVS vs PTGX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, PHVS is priced at $31.59, while PTGX trades at $98.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas PTGX's P/E ratio is -54.16. In terms of profitability, PHVS's ROE is -0.67%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, PHVS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PTGX's competition here
PHVS vs TGTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TGTX has a market cap of 6.3B. Regarding current trading prices, PHVS is priced at $31.59, while TGTX trades at $40.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TGTX's P/E ratio is 14.32. In terms of profitability, PHVS's ROE is -0.67%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, PHVS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check TGTX's competition here
PHVS vs CNTA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, PHVS is priced at $31.59, while CNTA trades at $39.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CNTA's P/E ratio is -22.30. In terms of profitability, PHVS's ROE is -0.67%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PHVS is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CNTA's competition here
PHVS vs KYMR Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, KYMR has a market cap of 6.1B. Regarding current trading prices, PHVS is priced at $31.59, while KYMR trades at $73.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas KYMR's P/E ratio is -20.66. In terms of profitability, PHVS's ROE is -0.67%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, PHVS is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KYMR's competition here
PHVS vs RYTM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, PHVS is priced at $31.59, while RYTM trades at $85.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RYTM's P/E ratio is -27.45. In terms of profitability, PHVS's ROE is -0.67%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, PHVS is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RYTM's competition here
PHVS vs PTCT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, PHVS is priced at $31.59, while PTCT trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas PTCT's P/E ratio is -27.90. In terms of profitability, PHVS's ROE is -0.67%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, PHVS is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check PTCT's competition here
PHVS vs LEGN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, LEGN has a market cap of 5.8B. Regarding current trading prices, PHVS is priced at $31.59, while LEGN trades at $31.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas LEGN's P/E ratio is -22.84. In terms of profitability, PHVS's ROE is -0.67%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, PHVS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check LEGN's competition here
PHVS vs LQDA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, LQDA has a market cap of 5.7B. Regarding current trading prices, PHVS is priced at $31.59, while LQDA trades at $63.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas LQDA's P/E ratio is 375.88. In terms of profitability, PHVS's ROE is -0.67%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, PHVS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check LQDA's competition here
PHVS vs CDTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PHVS is priced at $31.59, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PHVS's ROE is -0.67%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, PHVS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CDTX's competition here
PHVS vs BLTE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, BLTE has a market cap of 5.6B. Regarding current trading prices, PHVS is priced at $31.59, while BLTE trades at $139.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas BLTE's P/E ratio is -54.97. In terms of profitability, PHVS's ROE is -0.67%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, PHVS is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check BLTE's competition here
PHVS vs ABCM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $31.59, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PHVS's ROE is -0.67%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PHVS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ABCM's competition here
PHVS vs ISEE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PHVS is priced at $31.59, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PHVS's ROE is -0.67%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PHVS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ISEE's competition here
PHVS vs PRAX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, PRAX has a market cap of 5.4B. Regarding current trading prices, PHVS is priced at $31.59, while PRAX trades at $253.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas PRAX's P/E ratio is -18.91. In terms of profitability, PHVS's ROE is -0.67%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, PHVS is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check PRAX's competition here
PHVS vs COGT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, PHVS is priced at $31.59, while COGT trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas COGT's P/E ratio is -14.36. In terms of profitability, PHVS's ROE is -0.67%, compared to COGT's ROE of -0.83%. Regarding short-term risk, PHVS is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check COGT's competition here
PHVS vs FBIOX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, PHVS is priced at $31.59, while FBIOX trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas FBIOX's P/E ratio is N/A. In terms of profitability, PHVS's ROE is -0.67%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, PHVS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check FBIOX's competition here
PHVS vs APLS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PHVS is priced at $31.59, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas APLS's P/E ratio is 38.35. In terms of profitability, PHVS's ROE is -0.67%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PHVS is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check APLS's competition here
PHVS vs SRRK Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, SRRK has a market cap of 5.2B. Regarding current trading prices, PHVS is priced at $31.59, while SRRK trades at $43.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas SRRK's P/E ratio is -12.70. In terms of profitability, PHVS's ROE is -0.67%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, PHVS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check SRRK's competition here
PHVS vs APGE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, PHVS is priced at $31.59, while APGE trades at $83.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas APGE's P/E ratio is -19.17. In terms of profitability, PHVS's ROE is -0.67%, compared to APGE's ROE of -0.33%. Regarding short-term risk, PHVS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check APGE's competition here
PHVS vs CRSP Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, PHVS is priced at $31.59, while CRSP trades at $51.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CRSP's P/E ratio is -8.36. In terms of profitability, PHVS's ROE is -0.67%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, PHVS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CRSP's competition here
PHVS vs CGON Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, PHVS is priced at $31.59, while CGON trades at $54.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CGON's P/E ratio is -23.25. In terms of profitability, PHVS's ROE is -0.67%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PHVS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CGON's competition here
PHVS vs TERN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PHVS is priced at $31.59, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TERN's P/E ratio is -51.41. In terms of profitability, PHVS's ROE is -0.67%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PHVS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TERN's competition here
PHVS vs LGND Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, LGND has a market cap of 4.8B. Regarding current trading prices, PHVS is priced at $31.59, while LGND trades at $237.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas LGND's P/E ratio is 30.96. In terms of profitability, PHVS's ROE is -0.67%, compared to LGND's ROE of +0.16%. Regarding short-term risk, PHVS is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check LGND's competition here
PHVS vs MIRM Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, PHVS is priced at $31.59, while MIRM trades at $93.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MIRM's P/E ratio is -6.88. In terms of profitability, PHVS's ROE is -0.67%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, PHVS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MIRM's competition here
PHVS vs CAI Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, PHVS is priced at $31.59, while CAI trades at $16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CAI's P/E ratio is -5.85. In terms of profitability, PHVS's ROE is -0.67%, compared to CAI's ROE of +0.06%. Regarding short-term risk, PHVS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CAI's competition here
PHVS vs FOLD Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $31.59, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PHVS's ROE is -0.67%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PHVS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check FOLD's competition here
PHVS vs AKRO Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $31.59, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PHVS's ROE is -0.67%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, PHVS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check AKRO's competition here
PHVS vs ALPN Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PHVS is priced at $31.59, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PHVS's ROE is -0.67%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PHVS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ALPN's competition here
PHVS vs TVTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, PHVS is priced at $31.59, while TVTX trades at $47.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TVTX's P/E ratio is -94.16. In terms of profitability, PHVS's ROE is -0.67%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, PHVS is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check TVTX's competition here
PHVS vs SYRE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, PHVS is priced at $31.59, while SYRE trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas SYRE's P/E ratio is -33.96. In terms of profitability, PHVS's ROE is -0.67%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, PHVS is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check SYRE's competition here
PHVS vs CELC Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, PHVS is priced at $31.59, while CELC trades at $87.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CELC's P/E ratio is -22.42. In terms of profitability, PHVS's ROE is -0.67%, compared to CELC's ROE of -2.45%. Regarding short-term risk, PHVS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check CELC's competition here
PHVS vs OPT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PHVS is priced at $31.59, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas OPT's P/E ratio is -1.52. In terms of profitability, PHVS's ROE is -0.67%, compared to OPT's ROE of +1.09%. Regarding short-term risk, PHVS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check OPT's competition here
PHVS vs MRTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PHVS is priced at $31.59, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PHVS's ROE is -0.67%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PHVS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check MRTX's competition here
PHVS vs XENE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, PHVS is priced at $31.59, while XENE trades at $51.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas XENE's P/E ratio is -10.90. In terms of profitability, PHVS's ROE is -0.67%, compared to XENE's ROE of -0.49%. Regarding short-term risk, PHVS is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check XENE's competition here
PHVS vs ERAS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ERAS has a market cap of 4B. Regarding current trading prices, PHVS is priced at $31.59, while ERAS trades at $12.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ERAS's P/E ratio is -13.84. In terms of profitability, PHVS's ROE is -0.67%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, PHVS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check ERAS's competition here
PHVS vs CPRX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $31.59, while CPRX trades at $31.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CPRX's P/E ratio is 18.08. In terms of profitability, PHVS's ROE is -0.67%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PHVS is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CPRX's competition here
PHVS vs MANE Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, MANE has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $31.59, while MANE trades at $90.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas MANE's P/E ratio is -34.12. In terms of profitability, PHVS's ROE is -0.67%, compared to MANE's ROE of -0.95%. Regarding short-term risk, PHVS is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check MANE's competition here
PHVS vs VCYT Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $31.59, while VCYT trades at $47.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas VCYT's P/E ratio is 43.77. In terms of profitability, PHVS's ROE is -0.67%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, PHVS is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check VCYT's competition here
PHVS vs RYZB Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PHVS is priced at $31.59, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PHVS's ROE is -0.67%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PHVS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check RYZB's competition here
PHVS vs EWTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $31.59, while EWTX trades at $34.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas EWTX's P/E ratio is -20.99. In terms of profitability, PHVS's ROE is -0.67%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, PHVS is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check EWTX's competition here
PHVS vs CBAY Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $31.59, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PHVS's ROE is -0.67%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PHVS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CBAY's competition here
PHVS vs ACAD Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $31.59, while ACAD trades at $21.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas ACAD's P/E ratio is 9.82. In terms of profitability, PHVS's ROE is -0.67%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, PHVS is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check ACAD's competition here
PHVS vs KNSA Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, PHVS is priced at $31.59, while KNSA trades at $49.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas KNSA's P/E ratio is 53.89. In terms of profitability, PHVS's ROE is -0.67%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, PHVS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check KNSA's competition here
PHVS vs NAMS Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, PHVS is priced at $31.59, while NAMS trades at $30.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas NAMS's P/E ratio is -17.39. In terms of profitability, PHVS's ROE is -0.67%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, PHVS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check NAMS's competition here
PHVS vs TNGX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, PHVS is priced at $31.59, while TNGX trades at $30.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TNGX's P/E ratio is -37.27. In terms of profitability, PHVS's ROE is -0.67%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, PHVS is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check TNGX's competition here
PHVS vs SWTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PHVS is priced at $31.59, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PHVS's ROE is -0.67%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, PHVS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check SWTX's competition here
PHVS vs CRNX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, CRNX has a market cap of 3.5B. Regarding current trading prices, PHVS is priced at $31.59, while CRNX trades at $33.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas CRNX's P/E ratio is -6.51. In terms of profitability, PHVS's ROE is -0.67%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PHVS is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check CRNX's competition here
PHVS vs VKTX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, PHVS is priced at $31.59, while VKTX trades at $29.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas VKTX's P/E ratio is -7.05. In terms of profitability, PHVS's ROE is -0.67%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, PHVS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check VKTX's competition here
PHVS vs DNTH Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, PHVS is priced at $31.59, while DNTH trades at $81.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas DNTH's P/E ratio is -19.20. In terms of profitability, PHVS's ROE is -0.67%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, PHVS is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for PHVS.Check DNTH's competition here
PHVS vs TLX Comparison June 2026
PHVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHVS stands at 2.2B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, PHVS is priced at $31.59, while TLX trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHVS currently has a P/E ratio of -10.00, whereas TLX's P/E ratio is -461.00. In terms of profitability, PHVS's ROE is -0.67%, compared to TLX's ROE of -0.02%. Regarding short-term risk, PHVS is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for PHVS.Check TLX's competition here